Education
About Us
Working with TipRanks
Follow Us
Repligen (RGEN)
NASDAQ:RGEN
RGEN Stock Chart & Stats
$125.03
$0.11(0.07%)
At close: 4:00 PM EST
$125.03
$0.11(0.07%)
Day’s Range― - ―
52-Week Range$102.97 - $175.77
Previous CloseN/A
Volume111.19K
Average Volume (3M)785.46K
Market Cap
$7.04B
Enterprise Value$7.17B
Total Cash (Recent Filing)$767.63M
Total Debt (Recent Filing)$689.95M
Price to Earnings (P/E)188.5
Beta0.96
Next Earnings
May 05, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.49
Shares Outstanding56,331,110
10 Day Avg. Volume945,299
30 Day Avg. Volume785,463
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.38
Price to Sales (P/S)12.48
P/FCF Ratio98.13
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue9.71
Enterprise Value/Gross Profit19.07
Enterprise Value/Ebitda40.57
Forecast
1Y Price Target
$188.00Price Target Upside50.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)1.99
Revenue Forecast (FY)$826.85M
Bulls Say, Bears Say
Bulls Say
Order Momentum And Broad-based DemandSustained order momentum across analytics, proteins, and bioprocessing franchises, driven by demand from pharmaceutical and emerging biotech customers, indicates durable revenue growth potential.
Product Innovation And PipelineAn expanding pipeline that includes newly launched chromatography resins and a planned combined ATF and MAVERICK product supports future top-line growth and strengthens competitive positioning in bioprocessing.
Strategic Commercial Expansion And Valuation SupportExpanded presence in Asia and targeted commercial investments in key accounts enhance market access and could unlock upside to a valuation that currently lags long-term levels.
Bears Say
Conservative Guidance And Margin PressureFormal guidance that is conservative for revenue and profit, with adjusted margin targets below some expectations, may constrain near-term upside and create margin pressure.
Customer Ordering DelaysOrdering delays from pharmaceutical customers who are evaluating supplier deal terms are creating demand headwinds that could slow revenue progression.
Limited Growth VisibilityLimited visibility into longer-term growth drivers raises uncertainty since current share levels may already reflect anticipated margin improvement and expansion.
Repligen News
RGEN FAQ
What was Repligen’s price range in the past 12 months?
Repligen lowest stock price was $102.97 and its highest was $175.77 in the past 12 months.
What is Repligen’s market cap?
Repligen’s market cap is $7.04B.
When is Repligen’s upcoming earnings report date?
Repligen’s upcoming earnings report date is May 05, 2026 which is in 59 days.
How were Repligen’s earnings last quarter?
Repligen released its earnings results on Feb 24, 2026. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05.
Is Repligen overvalued?
According to Wall Street analysts Repligen’s price is currently Undervalued.
Does Repligen pay dividends?
Repligen does not currently pay dividends.
What is Repligen’s EPS estimate?
Repligen’s EPS estimate is 0.39.
How many shares outstanding does Repligen have?
Repligen has 56,331,110 shares outstanding.
What happened to Repligen’s price movement after its last earnings report?
Repligen reported an EPS of $0.49 in its last earnings report, beating expectations of $0.44. Following the earnings report the stock price went down -0.539%.
Which hedge fund is a major shareholder of Repligen?
Currently, no hedge funds are holding shares in RGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Repligen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$188.00 (50.36% Upside)
$188.00 (50.36% Upside)
Blogger Sentiment
Bullish
RGEN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $44.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 7.1%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.70%
12-Months-Change
Fundamentals
Return on Equity
2.40%
Trailing 12-Months
Asset Growth
4.24%
Trailing 12-Months
Company Description
Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
RGEN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive and optimistic: management reported solid revenue acceleration (Q4 and full‑year growth above expectations), meaningful margin expansion, strong cash generation, successful product launches and acquisition integrations, and provided growth and margin guidance for 2026. The company also highlighted several near-term headwinds—muted capital equipment demand, a gene therapy customer-facing headwind, tariff and policy uncertainty, M&A/FX dilution to reported margins, and increased investments in Fit-for-Growth—that temper upside visibility. On balance, the positives (broad-based franchise strength, margin expansion, strong cash and funnel, and prudent but constructive guidance) substantially outweigh the cited risks.View all RGEN earnings summariesRGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGEN Stock 12 Month Forecast
Average Price Target
$188.00
▲(50.36% Upside)
Technical Analysis
AptarGroup
―
Merit Medical Systems
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
0.63% Insiders
38.26% Mutual Funds
15.12% Other Institutional Investors
24.40% Public Companies and
Individual Investors